CRDL (Cardiol Therapeutics) Net Income Including Noncontrolling Interests : $-25.72 Mil (TTM As of Mar. 2025)

View and export this data going back to 2019. Start your Free Trial

What is Cardiol Therapeutics Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Cardiol Therapeutics's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2025 was $-5.77 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2025 was $-25.72 Mil.

Cardiol Therapeutics Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Cardiol Therapeutics's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiol Therapeutics Net Income Including Noncontrolling Interests Chart

Cardiol Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Income Including Noncontrolling Interests

Get a 7-Day Free Trial

-16.11

-24.72

-22.77

-20.97

-25.74

Cardiol Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Income Including Noncontrolling Interests	Get a 7-Day Free Trial															-6.78	-4.81	-9.40	-5.74	-5.77

Cardiol Therapeutics Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-25.72 Mil.

Cardiol Therapeutics Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Cardiol Therapeutics's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Cardiol Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cardiol Therapeutics Inc (NAS:CRDL) » Definitions » Net Income Including Noncontrolling Interests

Comparable Companies

Traded in Other Exchanges

CT9:Germany CRDL:Canada

Address

2265 Upper Middle Road East, Suite 602, Oakville, ON, CAN, L6H 0G5

Website

https://www.cardiolrx.com

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.